Capricor Therapeutics, Inc. (CAPR): Price and Financial Metrics
CAPR Price/Volume Stats
| Current price | $4.71 | 52-week high | $6.58 |
| Prev. close | $4.69 | 52-week low | $3.30 |
| Day low | $4.68 | Volume | 17,448 |
| Day high | $4.76 | Avg. volume | 81,532 |
| 50-day MA | $4.25 | Dividend yield | N/A |
| 200-day MA | $4.65 | Market Cap | 119.02M |
CAPR Stock Price Chart Interactive Chart >
CAPR POWR Grades
- Sentiment is the dimension where CAPR ranks best; there it ranks ahead of 81.14% of US stocks.
- CAPR's strongest trending metric is Stability; it's been moving up over the last 179 days.
- CAPR ranks lowest in Momentum; there it ranks in the 5th percentile.
CAPR Stock Summary
- For CAPR, its debt to operating expenses ratio is greater than that reported by merely 12.13% of US equities we're observing.
- CAPR's price/sales ratio is 21.4; that's higher than the P/S ratio of 94.57% of US stocks.
- As for revenue growth, note that CAPR's revenue has grown 2,613.7% over the past 12 months; that beats the revenue growth of 99.5% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to CAPRICOR THERAPEUTICS INC are ARCT, MRKR, MRSN, STOK, and EFTR.
- CAPR's SEC filings can be seen here. And to visit CAPRICOR THERAPEUTICS INC's official web site, go to www.capricor.com.
CAPR Valuation Summary
- CAPR's price/earnings ratio is -4.1; this is 117.01% lower than that of the median Healthcare stock.
- Over the past 195 months, CAPR's EV/EBIT ratio has gone down 3.8.
Below are key valuation metrics over time for CAPR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CAPR | 2023-05-23 | 21.6 | 19.3 | -4.1 | -3.9 |
| CAPR | 2023-05-22 | 21.3 | 19.0 | -4.1 | -3.8 |
| CAPR | 2023-05-19 | 20.5 | 18.3 | -3.9 | -3.6 |
| CAPR | 2023-05-18 | 21.1 | 18.8 | -4.0 | -3.7 |
| CAPR | 2023-05-17 | 19.8 | 17.7 | -3.8 | -3.5 |
| CAPR | 2023-05-16 | 19.3 | 17.3 | -3.7 | -3.4 |
CAPR Growth Metrics
- Its year over year net cashflow from operations growth rate is now at 186.85%.
- Its year over year price growth rate is now at -18.51%.
- Its 3 year net income to common stockholders growth rate is now at -61.61%.
The table below shows CAPR's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1.591566 | 6.191106 | -27.48914 |
| 2022-06-30 | 0 | 8.538784 | -25.04984 |
| 2022-03-31 | 0.204082 | 10.56661 | -22.68869 |
| 2021-12-31 | 0.244898 | -16.80932 | -20.02252 |
| 2021-09-30 | 0.302728 | -15.02414 | -18.00993 |
| 2021-06-30 | 0.319591 | -14.66378 | -17.98824 |
CAPR's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CAPR has a Quality Grade of D, ranking ahead of 11.34% of graded US stocks.
- CAPR's asset turnover comes in at 0.008 -- ranking 401st of 682 Pharmaceutical Products stocks.
- DRNA, MYMD, and PCRX are the stocks whose asset turnover ratios are most correlated with CAPR.
The table below shows CAPR's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.008 | 1 | 14.774 |
| 2021-03-31 | 0.004 | 1 | 15.634 |
| 2020-12-31 | 0.010 | 1 | 19.771 |
| 2020-09-30 | 0.019 | 1 | -10.307 |
| 2020-06-30 | 0.034 | 1 | -6.657 |
| 2020-03-31 | 0.095 | 1 | -5.229 |
CAPR Price Target
For more insight on analysts targets of CAPR, see our CAPR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.50 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Capricor Therapeutics, Inc. (CAPR) Company Bio
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company was founded in 2005 and is based in Beverly Hills, California.
Latest CAPR News From Around the Web
Below are the latest news stories about CAPRICOR THERAPEUTICS INC that investors may wish to consider to help them evaluate CAPR as an investment opportunity.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares Could Be 27% Above Their Intrinsic Value EstimateKey Insights Using the 2 Stage Free Cash Flow to Equity, Capricor Therapeutics fair value estimate is US$3.18 Capricor... |
Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); On Track to Report Interim Analysis in Fourth Quarter of 2023- -Plan to Present 24-Month HOPE-2 Open Label Extension Data in Second Quarter of 2023- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-b |
Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ETSAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023. Management will then host a webcast and conference |
Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform-Capricor’s StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics-SAN DIEGO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today the publication of a preclinical study in Microbiology Spectrum, a leading peer-reviewed scient |
Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceLate-Breaking Presentation Highlighted Positive18-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy PatientsSAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company presented the 18-month results from its HOPE-2 open- |
CAPR Price Returns
| 1-mo | 16.87% |
| 3-mo | 1.51% |
| 6-mo | 23.62% |
| 1-year | 27.64% |
| 3-year | 0.86% |
| 5-year | -62.62% |
| YTD | 22.02% |
| 2022 | 31.74% |
| 2021 | -14.58% |
| 2020 | 167.97% |
| 2019 | -68.78% |
| 2018 | -74.05% |
Continue Researching CAPR
Want to do more research on Capricor Therapeutics Inc's stock and its price? Try the links below:Capricor Therapeutics Inc (CAPR) Stock Price | Nasdaq
Capricor Therapeutics Inc (CAPR) Stock Quote, History and News - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...